

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

Notes of the meeting of the South and West Devon Formulary Interface Group

Friday 11th July 2014, 2pm – 4.30pm

The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

Present:	Chris Roome (CR) – Head of Clinical Effectiveness Gareth Franklin (GF) – Clinical Guidance Manager Iain Roberts (IR) – Lead MO Pharmacist Emma Hewitt (EH) – Joint Formulary Pharmacist Larissa Sullivan (LS) – Interface Pharmacist Andrew Gunatilleke (AG) – Consultant, Chair SDNT DTC Elena Mercer (EM) – Formulary Pharmacist Keith Gillespie (KG) – GP Bill Nolan (BN) – GP Jeremy Morris – Formulary Pharmacist Larissa Sullivan (LS) – Interface Pharmacist Steve Cooke (SC) – Chief Pharmacist Phil Melliush (PM) – GP Paul Manson (PLM) – Lead MO Pharmacist	NEW Devon CCG NEW Devon CCG South Devon & Torbay CCG NEW Devon CCG NEW Devon CCG South Devon NHS Trust South Devon NHS Trust NEW Devon CCG South Devon & Torbay CCG Plymouth Hospitals NHS Trust NEW Devon CCG Plymouth Community Healthcare South Devon & Torbay CCG NEW Devon CCG
Apologies	Carol Webb (CW) Amanda Gulbranson (AG) – Clinical Effectiveness Lead David Gwynne – GP Margaret Hinchliffe (MH)	NEW Devon CCG Devon Partnership Trust NEW Devon CCG Lay member
1.	Welcome: apologies as noted above.	
2.	Declarations of interest: None	
3.	<p>Notes of last meeting 13th June 2014: Discussion regarding nutrition and IV fluids Action: to contact dieticians regarding agreed common products and form a list of such products Action: to link back to in-house IV fluid lists from Formulary website</p>	
	<p>Action log: Items completed noted, items carried forward:</p> <ul style="list-style-type: none"> • Osteoporosis pathway – future agenda • Brand names for epilepsy treatments – future agenda • Guidance on measuring prolactin in patients taking anti psychotics - future agenda • To ascertain both CCGs what service is being commissioned in regard to reviewing patients taking drugs for dementia • Send Deborah Howland the re-formatted malnutrition tool 	
	<p>Frequency of meetings and future chair It was proposed that the chair should be a clinician Action: email the clinicians regarding volunteering for this role. It was agreed that the second Friday of every other month would be appropriate for future meetings. Consideration was given to email discussions and decisions of minor issues; drug</p>	

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

	placements post CPC and acknowledgement of NICE and National steered work-plans (TAGs).
4.	<p>Type 2 diabetes Treatment Guidance</p> <p>The guidance has been circulated to all specialists across the two acute trusts. It was decided the guidance was appropriate for publishing in the combined formulary. To be reviewed when new NICE guidance is published. It was suggested that the section on combination prescribing be re-worded to avoid this occurring as routine treatment.</p> <p>Action: to email IR and PM for suggestions for the dual products entry.</p> <p>Action: to ensure acronyms are expanded e.g. DPP-4 inhibitor</p>
5.	<p>Antidiabetic drugs</p> <p>The committee discussed the formulary choice sulphonylureas. GF to seek clarification from specialists re: glimepiride</p> <p>Action: to confirm reasoning of adding glimepiride with specialist</p> <p>The cost difference between metformin tablets and oral solution was considered to be significant and requires some notes regarding the patients for whom the oral solution is suitable.</p> <p>Action: to add in patient groups for whom the liquid preparation of metformin is suitable for</p> <p>The new GPP-4 inhibitor alogliptin was noted. A CPC application would be required for this new agent.</p> <p>Action: sitagliptin to be highlighted as the first line gliptin.</p> <p>Action: to review units of HbA1c (% vs mmol/mol) to ensure consistency</p>
7.	<p>Thyroid and antithyroid hormones</p> <p>Expanded guidance section to be developed with specialists and brought back to a future meeting.</p> <p>Action: to include hepatotoxicity as caution/contraindication for propylthiouracil</p>
8.	<p>Oestrogens for HRT</p> <p>It was noted that the drug monograph for raloxifene does not acknowledge the breast cancer prophylaxis guidance by NICE.</p> <p>Action: to consider notes/wording for the monograph entry and bring to future meeting for discussion.</p> <p>Action: to update indications for these products</p>
9.	<p>Male sex hormones and antagonists</p> <p>Discussion regarding the unlicensed use of testosterone for female to male transgender patients. Reference to gender clinics and cardiovascular risks relating to the drug were discussed. It was concluded that no amendments were to be made to the drug entry and any discussion regarding prescribing in such patients should be referred back to the specialist overseeing treatment for the individual patient.</p>
10.	<p>Hypothalamic and pituitary hormones and anti-oestrogens</p> <p>Commissioning between adults and children in relation to growth hormone is different, either the CCG or NHS England.</p> <p>Action: to check commissioning arrangements.</p>
11.	<p>Drugs affecting bone metabolism</p> <p>Denosumab, the formulary entry is to be published as it is now and reviewed after the outcome of the on-going Devon-wide discussions.</p>

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

	<p>Action: Denosumab injection to be highlighted as a specialist service provided by South Devon Trust only.</p> <p>Action: to check MHRA safety information relating to strontium is up to date.</p>
12.	<p>Other endocrine drugs</p> <p>It was asked that, although all amber drugs, triptorelin to be highlighted as the first-line treatment</p> <p>Action: to edit the formatting of triptorelin</p>
13.	<p>Recent drug decisions including NICE</p> <p>These were noted. Lisdexamfetamine will be brought to a joint Devon FIG due to mental health care boundaries not conforming to North/East and South/West divide.</p>
14.	<p>MHRA Drug Safety Update – May</p> <p>These were noted.</p> <p>Action: Any concerns to be highlighted to CW/GF by email.</p>
<p>Next meeting: Friday 12th September 2014 2pm – 4:30pm The Watermark, Ivybridge PL21 0SZ</p>	

South and West Devon Formulary Group – Action log

Date	Action	Responsible	Completed
June 2013	To bring a revised osteoporosis pathway to future meeting	GF	
Dec 13	Brand names for epilepsy treatments <ul style="list-style-type: none"> • To brief the committee on this when available 	IR	
June 14	To ascertain both CCGs what service is being commissioned in regard to reviewing patients taking drugs for dementia	AG	
June 14	Send Deborah Howland the re-formatted malnutrition tool	CW	Complete
July 14	Agreement of new clinical chair	CR	
July 14	Contact dieticians regarding agreed common products and form an appropriate list	CR	
July 14	Amendments relating to website formatting and appropriate wording for endocrinology chapter	GF	
July 14	Raloxifene and breast cancer prophylaxis – formulary position	CR	
July 14	Growth hormone commissioning arrangements to be confirmed	CR	